Where does Sumitomo Dainippon Pharma Oncology, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Sumitomo Dainippon Pharma Oncology, Inc. ranks #23,477 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Sumitomo Dainippon Pharma Oncology, Inc. hold?

Sumitomo Dainippon Pharma Oncology, Inc. holds 12 US utility patents granted between 2020 and 2022, spanning 7 technology areas.

What is Sumitomo Dainippon Pharma Oncology, Inc.'s Innovation Score?

Sumitomo Dainippon Pharma Oncology, Inc. has an Innovation Score of 27.2 out of 100 (23rd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Sumitomo Dainippon Pharma Oncology, Inc. focus on?

Sumitomo Dainippon Pharma Oncology, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 10 patents, ranking #1,884 of 6,058 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is Sumitomo Dainippon Pharma Oncology, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Sumitomo Dainippon Pharma Oncology, Inc..

What does claim depth mean for Sumitomo Dainippon Pharma Oncology, Inc.'s patents?

Sumitomo Dainippon Pharma Oncology, Inc.'s patents average 12.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Sumitomo Dainippon Pharma Oncology, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Sumitomo Dainippon Pharma Oncology, Inc.

USPTO PatentsView assignee record - 12 granted patents across 7 technology areas, recorded in grant years 2020–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Sumitomo ranks #23,477 of 49,997 tracked US assignees by granted-patent volume, with 12 patents across 7 technology areas.

#23,477
of 49,997 US assignees by volume: 23rd percentile
by Innovation Score (27.2/100): 12.8
avg claims per patent

USPTO PatentsView assignee plate

Corpus R23477 · US Corporation #23,477 · 12 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 12 grants
MID-PACK #23,477/49,997
PHOTO-FINISH Stego Industries
CPC-NARROW A61P · 7 areas
INNOV-THIN 27.2/100
CLAIMS-RICH 12.8 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2020–2022 · 3y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Stego Industries, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Sumitomo’s 27.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.9 pts (33%) Velocity 1.3 pts (5%) Breadth 9.4 pts (34%) Claim depth 7.7 pts (28%)

Qualcomm Incorporated · highest

85
Sumitomo Dainippon… · this assignee

27
3D Lighting… · lowest

7

What this shows Sumitomo's Innovation Score is 27.2/100 (23rd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Sumitomo?

Each dot is one of Sumitomo’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Sumitomo’s own 12.8 claims/patent is at or below the 19.4 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Sumitomo vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Sumitomo's grants concentrate

Sumitomo Dainippon Pharma Oncology, Inc. is a focused PatentsView assignee: 7 CPC subclasses with 83.3% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2020 (5 grants) versus a trough of 2 in 2022. By volume, Sumitomo sits between Stego Industries, LLC and Surgimatix, Inc..

Sumitomo's three-year grant acceleration

Sumitomo Dainippon Pharma Oncology, Inc. shows 2 grants in 2022–2024 against only 10 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Stego Industries

12
Straxcorp Pty

12
Sturman Digital S…

12
Subsea 7 do Brasi…

12
Sundrop Fuels

12
Superb AI

12
Surfacide

12
Surgimatix

12
Sumitomo Dainippo… ◀

12

What this shows Sumitomo holds 12 patents at rank #23,476, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Sumitomo

By rank, the assignees closest to #23,476 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Sumitomo's primary technology class.

Sumitomo's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

27 23rd percentile higher than 23% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

Sumitomo Dainippon Pharma Oncology, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	5	41.7%
2021	5	41.7%
2022	2	16.7%

Which technologies does Sumitomo Dainippon Pharma Oncology, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 10

C07D - Heterocyclic Compounds 10

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 8

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 3

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 2

C07C - Acyclic OR Carbocyclic Compounds 2

Y02A - Technologies FOR Adaptation TO Climate Change 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Sumitomo Dainippon Pharma Oncology, Inc.'s patent record in context - here's where to go next.

Sumitomo Dainippon Pharma Oncology, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 83.3% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #23,477 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Sumitomo Dainippon Pharma Oncology, Inc. against Stego Industries, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 27.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.